Autoimmune Diseases  >>  Nanozora (ozoralizumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Nanozora (ozoralizumab) / Sanofi, Taisho
NCT01063803: Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis

Checkmark P2 data - ACR/ARHP 2012 (RA)
Sep 2012 - Sep 2012: P2 data - ACR/ARHP 2012 (RA)
Checkmark P2 data (RA)
Jun 2012 - Jun 2012: P2 data (RA)
Completed
2
266
Japan, US, Canada, Europe, RoW
ATN-103
Ablynx
Rheumatoid Arthritis
02/12
02/12
NCT01007175: Study Evaluating Multiple Ascending Doses Of ATN-103 In Japanese Subjects With Rheumatoid Arthritis

Completed
1/2
60
Japan
ATN-103 10 mg q4wks, ATN-103 30 mg q4wks, ATN-103 80 mg q4wks, ATN-103 10 mg q8wks, ATN-103 80 mg q8wks
Ablynx
Rheumatoid Arthritis
09/10
09/10
NCT00959036: Study Evaluating Multiple Doses Of ATN-103 In Subjects With Active Rheumatoid Arthritis

Checkmark P2 POC Data
May 2012 - May 2012: P2 POC Data
Checkmark Data
Sep 2011 - Sep 2011: Data
Checkmark Data
More
Completed
1/2
252
US, Canada, Europe, RoW
ATN-103, Placebo, Methotrexate
Ablynx
Active Rheumatoid Arthritis
01/11
01/11

Download Options